AUTL
HEALTHCAREAutolus Therapeutics plc
$1.70+0.06 (+3.66%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AUTL Today?
No stock-specific AI insight has been generated for AUTL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.18$2.70
$1.70
Fundamentals
Market Cap$452M
P/E Ratio—
EPS$-1.08
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding266.1M
AUTL News
21 articles- European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday TradingYahoo Finance·May 7, 2026
- 3 Promising Penny Stocks With Market Caps Up To $900MYahoo Finance·May 5, 2026
- Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026Yahoo Finance·May 5, 2026
- How The Narrative On Autolus Therapeutics (AUTL) Is Shifting After Analyst Target ResetsYahoo Finance·May 4, 2026
- European Equities Traded in the US as American Depositary Receipts Start Week LowerYahoo Finance·May 4, 2026
- Is Autolus Therapeutics (AUTL) One of the Best Biotech Penny Stocks to Buy in 2026?Yahoo Finance·May 1, 2026
- Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionYahoo Finance·Apr 29, 2026
- European Equities Traded in the US as American Depositary Receipts Decline TuesdayYahoo Finance·Apr 28, 2026
- European Equities Traded in the US as American Depositary Receipts Track Lower in Monday TradingYahoo Finance·Apr 27, 2026
- European Equities Traded in the US as American Depositary Receipts Rise in Friday TradingYahoo Finance·Apr 24, 2026
- Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 21, 2026
- How The Autolus Therapeutics (AUTL) Narrative Is Shifting With Recalibrated Targets And Fair ValueYahoo Finance·Apr 20, 2026
- Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin TurnaroundMarketbeat·Apr 13, 2026
- Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric DataMarketbeat·Apr 8, 2026
- Autolus Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Apr 7, 2026
- Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12Yahoo Finance·Apr 4, 2026
- 3 Promising Penny Stocks With Market Caps Over $100MYahoo Finance·Apr 3, 2026
- Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?Yahoo Finance·Apr 1, 2026
- European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday TradingYahoo Finance·Mar 27, 2026
- Autolus Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 27, 2026
- Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdatesGlobeNewswire Inc.·Mar 27, 2026
All 21 articles loaded
Price Data
Open$1.68
Previous Close$1.64
Day High$1.75
Day Low$1.65
52 Week High$2.70
52 Week Low$1.18
52-Week Range
$1.18$2.70
$1.70
Fundamentals
Market Cap$452M
P/E Ratio—
EPS$-1.08
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding266.1M
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—